Company Description
Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2.
It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses.
The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022.
Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2020 |
| IPO Date | Aug 6, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 94 |
| CEO | David Hering M.B.A. |
Contact Details
Address: 1601 Trapelo Road, Suite 178 Waltham, Massachusetts 02451 United States | |
| Phone | (781) 819-0080 |
| Website | adagiotx.com |
Stock Details
| Ticker Symbol | IVVD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001832038 |
| CUSIP Number | 00534A102 |
| ISIN Number | US00534A1025 |
| Employer ID | 85-1403134 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David Hering M.B.A. | Chief Executive Officer and Director |
| Jill Andersen J.D. | Chief Legal Officer and Corporate Secretary |
| William E. Duke Jr., M.B.A. | Chief Financial Officer |
| Jeremy Gowler | Chief Operating Officer and Chief Commercial Officer |
| Stacy Price M.S. | Chief Technology and Manufacturing Officer |
| Dr. Robert D. Allen Ph.D. | Chief Scientific Officer |
| Scott Young | Senior Vice President of Investor Relations and Corporate Communications |
| Julie Green M.B.A. | Chief Human Resources Officer |
| Heidi Spurling M.S. | Vice President of Strategy and Operations and Chief of Staff to the Chief Executive Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | 8-K | Current Report |
| Apr 4, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 9, 2024 | 8-K | Current Report |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |